-
A phase I single-agent open-label dose-escalation study of oral ONC201 in patients with advanced solid tumors
Protocol: 051403
Principal Investigator: Mark Stein
Applicable Disease Sites: Kidney
Brain and Nervous System
Any Site
Breast - Male
Melanoma, skin
-
UPCC 02614: The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma:
A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma
Protocol: 091503
Principal Investigator: Janice Mehnert
Applicable Disease Sites: Melanoma, skin
-
The Development and Evaluation of a Behavioral Intervention to Reduce Indoor Tanning
Protocol: 131315
Principal Investigator: Jerod Stapleton
Applicable Disease Sites: Melanoma, skin
-
Sun Protection and Skin Self-Examination Among Families Coping With Early Onset Melanoma: A Pilot Study
Protocol: 131516
Principal Investigator: Sharon Manne
Applicable Disease Sites: Melanoma, skin
-
NCI/CTEP# 9466: Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma and other solid tumors
Protocol: 091306
Principal Investigator: Janice Mehnert
Applicable Disease Sites: Melanoma, skin
Any Site
-
EMR 100070-001: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical
activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.
Protocol: 051306
Principal Investigator: Howard Kaufman
Applicable Disease Sites: Bladder
Lung
Lip, Oral Cavity and Pharynx
Larynx
Melanoma, skin
Stomach
